IDEAYA Biosciences Soars 12.11% on Promising Cancer Drug Data

On September 8, 2025, IDEAYA Biosciences surged 12.11% in pre-market trading, marking a significant rise in its stock price.

IDEAYA Biosciences, in collaboration with Hengrui Pharma, has announced positive Phase 1 data for IDE849, a potential first-in-class DLL3 TOP1 ADC. This drug is being developed for the treatment of small cell lung cancer, and the data shows a 77.1% overall response rate, which is a promising development for the company's pipeline.

The positive Phase 1 data for IDE849 has been a key driver for the recent surge in IDEAYA Biosciences' stock price. The drug's potential as a first-in-class treatment for small cell lung cancer has generated significant interest among investors, who see it as a potential game-changer in the oncology market.

With the positive Phase 1 data for IDE849, IDEAYA Biosciences is well-positioned to continue its growth trajectory in the coming months. The company's focus on developing innovative cancer therapies has positioned it as a leader in the oncology market, and the positive data for IDE849 is a testament to its commitment to innovation and excellence.